89 related articles for article (PubMed ID: 17020990)
1. A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice.
Beumer JH; Joseph E; Egorin MJ; Parker RS; D'argenio DZ; Covey JM; Eiseman JL
Clin Cancer Res; 2006 Oct; 12(19):5826-33. PubMed ID: 17020990
[TBL] [Abstract][Full Text] [Related]
2. Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection.
Beumer JH; Joseph E; Egorin MJ; Covey JM; Eiseman JL
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):147-55. PubMed ID: 16364698
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine.
Holleran JL; Parise RA; Joseph E; Eiseman JL; Covey JM; Glaze ER; Lyubimov AV; Chen YF; D'Argenio DZ; Egorin MJ
Clin Cancer Res; 2005 May; 11(10):3862-8. PubMed ID: 15897587
[TBL] [Abstract][Full Text] [Related]
4. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.
Peters GJ; van Groeningen CJ; Laurensse EJ; Lankelma J; Leyva A; Pinedo HM
Cancer Chemother Pharmacol; 1987; 20(2):101-8. PubMed ID: 3664929
[TBL] [Abstract][Full Text] [Related]
5. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
[TBL] [Abstract][Full Text] [Related]
6. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy.
Ashour OM; Al Safarjalani ON; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2000; 45(5):351-61. PubMed ID: 10803917
[TBL] [Abstract][Full Text] [Related]
7. Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors.
Klecker RW; Cysyk RL; Collins JM
Bioorg Med Chem; 2006 Jan; 14(1):62-6. PubMed ID: 16143537
[TBL] [Abstract][Full Text] [Related]
8. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells.
Ben-Kasus T; Ben-Zvi Z; Marquez VE; Kelley JA; Agbaria R
Biochem Pharmacol; 2005 Jul; 70(1):121-33. PubMed ID: 15885659
[TBL] [Abstract][Full Text] [Related]
9. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
[TBL] [Abstract][Full Text] [Related]
10. [In vivo studies on the metabolism of pyrimidine nucleosides (author's transl)].
Dahnke HG; Mosebach KO
Hoppe Seylers Z Physiol Chem; 1975 Oct; 356(10):1565-74. PubMed ID: 1213673
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs.
Fulkerson CM; Dhawan D; Jones DR; Marquez VE; Jones PA; Wang Z; Wu Q; Klaunig JE; Fourez LM; Bonney PL; Knapp DW
Vet Comp Oncol; 2017 Mar; 15(1):226-236. PubMed ID: 26178438
[TBL] [Abstract][Full Text] [Related]
12. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine.
Davis ST; Joyner SS; Chandrasurin P; Baccanari DP
Biochem Pharmacol; 1993 Jan; 45(1):173-81. PubMed ID: 8424810
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.
Klecker RW; Jenkins JF; Kinsella TJ; Fine RL; Strong JM; Collins JM
Clin Pharmacol Ther; 1985 Jul; 38(1):45-51. PubMed ID: 4006375
[TBL] [Abstract][Full Text] [Related]
14. 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Al Safarjalani ON; Zhou XJ; Rais RH; Shi J; Schinazi RF; Naguib FN; El Kouni MH
Cancer Chemother Pharmacol; 2005 Jun; 55(6):541-51. PubMed ID: 15729584
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
16. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
17. Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.
Henricks LM; Jacobs BAW; Meulendijks D; Pluim D; van den Broek D; de Vries N; Rosing H; Beijnen JH; Huitema ADR; Guchelaar HJ; Cats A; Schellens JHM
Br J Clin Pharmacol; 2018 Dec; 84(12):2761-2769. PubMed ID: 30047584
[TBL] [Abstract][Full Text] [Related]
18. Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase.
Hahn RZ; Galarza AF; Schneider A; Antunes MV; Schwartsmann G; Linden R
Clin Biochem; 2015 Sep; 48(13-14):915-8. PubMed ID: 25940841
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
20. ADME studies of [5-(3)H]-2'-O-methyluridine nucleoside in mice: a building block in siRNA therapeutics.
Lozac'h F; Christensen J; Faller T; van de Kerkhof E; Krauser J; Garnier M; Litherland K; Catoire A; Natt F; Hunziker J; Swart P
Pharmacol Res Perspect; 2016 Feb; 4(1):e00209. PubMed ID: 26977299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
